FDA blasts Colombian drug manufacturer in warning letter for not properly addressing API flaws
When the FDA calls the quality of a drugmaker’s products into question, the worst possible response is “we can’t prove what we make is up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
